SOAT1 and cancer: Inhibition of the JAK-STAT signaling pathway has emerged as a prominent focus in targeted therapy for immune-mediated inflammatory diseases.[17] Dysregulation of the JAK-STAT signaling pathway has been implicated as a significant contributor to various diseases, particularly malignant tumors and autoimmune diseases.